Fig. 6.

A theranostic approach, presented by Bergmann et al. [17], used to monitor a novel immunotherapeutic technique (UniCAR T) based on site-directed target molecules that upon binding selectively turn on the immunotherapeutic action of T cells. A ⁶⁸Ga-PSMA targeting molecule is able to initialize the therapeutic effect and at the same time allows the targeting efficiency to be monitored by PET